Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Anti-MRSA agent 26

Copy Product Info
😃Good
Catalog No. T207519

Anti-MRSA agent 26 (compound 21) is an antibiotic that serves as a potent MRSA inhibitor. It exhibits a MIC of <0.015 μg/mL for MSSA and a MIC range of 0.015-0.06 μg/mL for MSSA, MRSE, and VRE. In a murine model of Staphylococcus aureus skin infection, Anti-MRSA agent 26 effectively clears the infection. It is a 7-deazapurine pyridine with potential application for treating topical infections caused by multidrug-resistant Gram-positive bacteria.

Anti-MRSA agent 26

Anti-MRSA agent 26

Copy Product Info
😃Good
Catalog No. T207519
Anti-MRSA agent 26 (compound 21) is an antibiotic that serves as a potent MRSA inhibitor. It exhibits a MIC of <0.015 μg/mL for MSSA and a MIC range of 0.015-0.06 μg/mL for MSSA, MRSE, and VRE. In a murine model of Staphylococcus aureus skin infection, Anti-MRSA agent 26 effectively clears the infection. It is a 7-deazapurine pyridine with potential application for treating topical infections caused by multidrug-resistant Gram-positive bacteria.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Anti-MRSA agent 26 (compound 21) is an antibiotic that serves as a potent MRSA inhibitor. It exhibits a MIC of <0.015 μg/mL for MSSA and a MIC range of 0.015-0.06 μg/mL for MSSA, MRSE, and VRE. In a murine model of Staphylococcus aureus skin infection, Anti-MRSA agent 26 effectively clears the infection. It is a 7-deazapurine pyridine with potential application for treating topical infections caused by multidrug-resistant Gram-positive bacteria.
In vitro
Anti-MRSA agent 26 (Compound 21) demonstrates no toxicity at a concentration of 10 μM towards Caco-2, DU-145, and MDCKII MDR1 cells within a 3-hour exposure. Furthermore, Anti-MRSA agent 26 exhibits remarkable activity against various Gram-positive pathogens, with a MIC of <0.015 μg/mL for MRSE, 0.015-0.03 μg/mL for MRSA, VRE1, VRE5, and 0.06 μg/mL for MSSA, when administered in the range of 0.015-16 μg/mL over 20-24 hours.
In vivo
Compound 21, an anti-MRSA agent, is applied as a 2% cream on wounds twice daily, with a 6-hour interval between applications, over a period of 5 days. This treatment significantly reduces bacterial load in a mouse model of Staphylococcus aureus skin infection.
Chemical Properties
FormulaC36H44N8O4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Anti-MRSA agent 26 | purchase Anti-MRSA agent 26 | Anti-MRSA agent 26 cost | order Anti-MRSA agent 26 | Anti-MRSA agent 26 in vivo | Anti-MRSA agent 26 in vitro | Anti-MRSA agent 26 formula